Home|Journals|Articles by Year|Audio Abstracts
 

Case Series

EJMCR. 2021; 5(8): 230-237


Two cases of aggressive sarcomatoid urothelial carcinoma reveal potential molecular targets

Alexandria M. Hertz, L. Angelica Lerma, Justin S. Ahn, Judith C. Hagedorn, Eric Q. Konnick, Robin L. Bennett, Petros Grivas, Michael J. Wagner, Nicholas P. Reder, Sarah P. Psutka.




Abstract
Cited by 0 Articles

Background: To detail two cases of sarcomatoid urothelial carcinoma (UC) with rapid progression, disseminated metastases, and early death, detailing the results of somatic tumor profiling using next-generation sequencing (NGS).
Case Series: The first case presented is a rare case of UC of the renal pelvis with osteosarcomatous differentiation and venous tumor thrombus in a 65-year-old man found to have a heterozygous germline variant of unknown significance in the neurofibromatosis-1 gene. The second case is a 72-year-old woman with sarcomatoid UC of the bladder. Herein, we discuss the presentation and clinical course, histology, immunohistochemical profiles, and somatic tumor testing results. We then review the literature regarding this rare and aggressive entity, detail options for optimal management, and address the role of molecular profiling in these cases.
Conclusion: Sarcomatoid UC is a rare and aggressive entity. NGS may be useful in these cases to guide systemic therapy.

Key words: Sarcomatoid, urothelial carcinoma, bladder cancer, renal mass, next-generation sequencing.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.